Reviewing Onconetix (NASDAQ:ONCO) and enGene (NASDAQ:ENGN)

Onconetix (NASDAQ:ONCO) and enGene (NASDAQ:ENGN) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, institutional ownership, analyst recommendations, earnings, profitability, dividends and valuation.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Onconetix and enGene, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Onconetix	1	0	0	0	1.00
enGene	2	8	4	0	2.14

enGene has a consensus price target of $11.05, suggesting a potential upside of 520.53%. Given enGene’s stronger consensus rating and higher probable upside, analysts clearly believe enGene is more favorable than Onconetix.

Profitability

This table compares Onconetix and enGene’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Onconetix	-1,575.89%	-91.95%	-53.76%
enGene	N/A	-56.06%	-45.64%

Earnings & Valuation

This table compares Onconetix and enGene”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Onconetix	$810,000.00	3.17	-$14.03 million	$248.12	0.00
enGene	N/A	N/A	-$117.30 million	($2.17)	-0.82

Onconetix has higher revenue and earnings than enGene. enGene is trading at a lower price-to-earnings ratio than Onconetix, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

23.9% of Onconetix shares are held by institutional investors. Comparatively, 64.2% of enGene shares are held by institutional investors. 0.3% of Onconetix shares are held by insiders. Comparatively, 10.5% of enGene shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Volatility & Risk

Onconetix has a beta of 2.69, suggesting that its share price is 169% more volatile than the S&P 500. Comparatively, enGene has a beta of -0.28, suggesting that its share price is 128% less volatile than the S&P 500.

Summary

enGene beats Onconetix on 8 of the 13 factors compared between the two stocks.

About Onconetix

Onconetix, Inc., a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology. It offers Entadfi, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia; and Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer. The company was formerly known as Blue Water Biotech, Inc. and changed its name to Onconetix, Inc. in December 2023. Onconetix, Inc. was incorporated in 2018 and is headquartered in Cincinnati, Ohio.

About enGene

enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.